{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:11:12Z","timestamp":1790802672586,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["P2022NMJEC"],"award-info":[{"award-number":["P2022NMJEC"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG29255"],"award-info":[{"award-number":["IG29255"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG30651"],"award-info":[{"award-number":["IG30651"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Catholic University of the Sacred Heart","doi-asserted-by":"publisher","award":["5x1000"],"award-info":[{"award-number":["5x1000"]}],"id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drup.2026.101354","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:13:44Z","timestamp":1767860024000},"page":"101354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer"],"prefix":"10.1016","volume":"85","author":[{"given":"Marco","family":"Pieraccioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ciucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-457X","authenticated-orcid":false,"given":"Roberta","family":"Mastrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora Kristina","family":"Scarpone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Piermattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5206-6867","authenticated-orcid":false,"given":"Floriana","family":"Camarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Tamagnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2864-8266","authenticated-orcid":false,"given":"Claudio","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2026.101354_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1541-7786.MCR-17-0594","article-title":"Molecular response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma","volume":"16","author":"Arend","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.drup.2026.101354_bib2","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1016\/j.ymthe.2024.06.029","article-title":"Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine","volume":"32","author":"Basnet","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drup.2026.101354_bib3","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1038\/s41467-024-50137-y","article-title":"Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer","volume":"15","author":"Burdett","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101354_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of Bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101354_bib5","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1158\/1078-0432.CCR-08-0479","article-title":"Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer","volume":"14","author":"Callahan","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101354_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101354_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-023-02682-5","article-title":"Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids","volume":"42","author":"Cesari","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101354_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13048-024-01471-8","article-title":"Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer","volume":"17","author":"Cooper","year":"2024","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.drup.2026.101354_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/s42003-024-06909-9","article-title":"The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells","volume":"7","author":"Croft","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.drup.2026.101354_bib10","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1073\/pnas.1314302110","article-title":"Synthetic lethality between CCNE1 amplification and loss of BRCA1","volume":"110","author":"Etemadmoghadam","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.drup.2026.101354_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114551","article-title":"Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer","volume":"43","author":"Frisbie","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.drup.2026.101354_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10050279","article-title":"CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.drup.2026.101354_bib13","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101354_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.500","article-title":"Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma","volume":"11","author":"Hao","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.drup.2026.101354_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","article-title":"The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells","volume":"37","author":"Hu","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drup.2026.101354_bib16","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1038\/ncomms8419","article-title":"Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours","volume":"6","author":"Ince","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2026.101354_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/0008-5472.CAN-21-1467","article-title":"Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer","volume":"82","author":"Javellana","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2026.101354_bib18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101354_bib19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.trecan.2025.03.005","article-title":"The future of tumor organoids in precision therapy","volume":"11","author":"Kim","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101354_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41577-024-01076-8","article-title":"Antigen presentation for central tolerance induction","volume":"25","author":"Klein","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drup.2026.101354_bib21","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.drup.2026.101354_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/mco.2022.2594","article-title":"Expression of MUC1 in different tumours and its clinical significance (Review)","volume":"17","author":"Lan","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101354_bib23","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2026.101354_bib24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2026.101354_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104813","article-title":"Unlock the code of MHC II-enabled Cancer immunotherapy","volume":"214","author":"Liu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2026.101354_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.trecan.2020.07.007","article-title":"Human-derived model systems in gynecological cancer research","volume":"6","author":"Lohmussaar","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drup.2026.101354_bib27","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","article-title":"Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors","volume":"187","author":"Luo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.drup.2026.101354_bib28","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.drup.2026.101354_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-025-09240-3","article-title":"Ongoing genome doubling shapes evolvability and immunity in ovarian cancer","author":"McPherson","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101354_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-021-01917-7","article-title":"Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine","volume":"40","author":"Nero","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.drup.2026.101354_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology\/gynecologic oncology group study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.drup.2026.101354_bib32","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Ovarian Tumor Tissue Analysis","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.drup.2026.101354_bib33","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A Phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2026.101354_bib34","article-title":"GPT2 mediates metabolic alterations in platinum-resistant ovarian cancer cells","author":"Ponton-Almodovar","year":"2025","journal-title":"Res Sq."},{"key":"10.1016\/j.drup.2026.101354_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104603","article-title":"The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features","volume":"208","author":"Santoro","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.drup.2026.101354_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41389-022-00419-1","article-title":"The impact of neoadjuvant chemotherapy on the tumor microenvironment in advanced high-grade serous carcinoma","volume":"11","author":"Shen","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.drup.2026.101354_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13048-024-01546-6","article-title":"Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors","volume":"17","author":"Udumula","year":"2024","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.drup.2026.101354_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102255","article-title":"PARP-inhibitors in epithelial ovarian cancer: actual positioning and future expectations","volume":"99","author":"Vanacker","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.drup.2026.101354_bib39","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drup.2026.101354_bib40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"Vazquez-Garcia","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.drup.2026.101354_bib41","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","article-title":"Heterogeneity and treatment landscape of ovarian carcinoma","volume":"20","author":"Veneziani","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.drup.2026.101354_bib42","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drup.2026.101354_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drup.2026.101354_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216928","article-title":"Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment","volume":"593","author":"Xu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2026.101354_bib45","article-title":"Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci. Adv."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764626000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:24:29Z","timestamp":1778804669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764626000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"alternative-id":["S1368764626000051"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2026.101354","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-cell transcriptome analysis of patient-derived organoids captures inter- and intratumor heterogeneity and uncovers targetable pathways in high grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2026.101354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101354"}}